Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells.

Davies AH, Reipas K, Hu K, Berns R, Firmino N, Stratford AL, Dunn SE.

Oncotarget. 2015 Aug 21;6(24):20570-7.

2.

The proto-oncogene PBF binds p53 and is associated with prognostic features in colorectal cancer.

Read ML, Seed RI, Modasia B, Kwan PP, Sharma N, Smith VE, Watkins RJ, Bansal S, Gagliano T, Stratford AL, Ismail T, Wakelam MJ, Kim DS, Ward ST, Boelaert K, Franklyn JA, Turnell AS, McCabe CJ.

Mol Carcinog. 2016 Jan;55(1):15-26. doi: 10.1002/mc.22254. Epub 2014 Nov 18.

PMID:
25408419
3.

YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer.

Davies AH, Reipas KM, Pambid MR, Berns R, Stratford AL, Fotovati A, Firmino N, Astanehe A, Hu K, Maxwell C, Mills GB, Dunn SE.

Stem Cells. 2014 Jun;32(6):1437-50. doi: 10.1002/stem.1707.

4.

The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells.

Read ML, Seed RI, Fong JC, Modasia B, Ryan GA, Watkins RJ, Gagliano T, Smith VE, Stratford AL, Kwan PK, Sharma N, Dixon OM, Watkinson JC, Boelaert K, Franklyn JA, Turnell AS, McCabe CJ.

Endocrinology. 2014 Apr;155(4):1222-34. doi: 10.1210/en.2013-1646. Epub 2014 Feb 7.

5.

Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.

Stratford AL, Reipas K, Hu K, Fotovati A, Brough R, Frankum J, Takhar M, Watson P, Ashworth A, Lord CJ, Lasham A, Print CG, Dunn SE.

Stem Cells. 2012 Jul;30(7):1338-48. doi: 10.1002/stem.1128.

6.

YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification.

Davies AH, Barrett I, Pambid MR, Hu K, Stratford AL, Freeman S, Berquin IM, Pelech S, Hieter P, Maxwell C, Dunn SE.

Oncogene. 2011 Aug 25;30(34):3649-60. doi: 10.1038/onc.2011.82. Epub 2011 Mar 21.

7.

The promise and challenges of targeting RSK for the treatment of cancer.

Stratford AL, Dunn SE.

Expert Opin Ther Targets. 2011 Jan;15(1):1-4. doi: 10.1517/14728222.2011.537656. No abstract available.

PMID:
21142801
8.

Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1.

Kalra J, Sutherland BW, Stratford AL, Dragowska W, Gelmon KA, Dedhar S, Dunn SE, Bally MB.

Oncogene. 2010 Dec 2;29(48):6343-56. doi: 10.1038/onc.2010.366. Epub 2010 Sep 13.

9.

Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer.

Stratford AL, Reipas K, Maxwell C, Dunn SE.

Expert Rev Mol Med. 2010 Jul 26;12:e22. doi: 10.1017/S1462399410001535. Review.

PMID:
20653987
10.

Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance.

To K, Fotovati A, Reipas KM, Law JH, Hu K, Wang J, Astanehe A, Davies AH, Lee L, Stratford AL, Raouf A, Johnson P, Berquin IM, Royer HD, Eaves CJ, Dunn SE.

Cancer Res. 2010 Apr 1;70(7):2840-51. doi: 10.1158/0008-5472.CAN-09-3155. Epub 2010 Mar 23. Erratum in: Cancer Res. 2018 Jul 15;78(14):4102.

11.

The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.

Astanehe A, Finkbeiner MR, Hojabrpour P, To K, Fotovati A, Shadeo A, Stratford AL, Lam WL, Berquin IM, Duronio V, Dunn SE.

Oncogene. 2009 Jun 25;28(25):2406-18. doi: 10.1038/onc.2009.81. Epub 2009 May 11.

PMID:
19430491
12.

Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells.

Finkbeiner MR, Astanehe A, To K, Fotovati A, Davies AH, Zhao Y, Jiang H, Stratford AL, Shadeo A, Boccaccio C, Comoglio P, Mertens PR, Eirew P, Raouf A, Eaves CJ, Dunn SE.

Oncogene. 2009 Mar 19;28(11):1421-31. doi: 10.1038/onc.2008.485. Epub 2009 Jan 19.

PMID:
19151767
13.

Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE.

Cancer Res. 2008 Dec 15;68(24):10238-46. doi: 10.1158/0008-5472.CAN-08-2755.

14.

Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.

Stratford AL, Fry CJ, Desilets C, Davies AH, Cho YY, Li Y, Dong Z, Berquin IM, Roux PP, Dunn SE.

Breast Cancer Res. 2008;10(6):R99. doi: 10.1186/bcr2202. Epub 2008 Nov 27.

15.

Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy.

Stratford AL, Habibi G, Astanehe A, Jiang H, Hu K, Park E, Shadeo A, Buys TP, Lam W, Pugh T, Marra M, Nielsen TO, Klinge U, Mertens PR, Aparicio S, Dunn SE.

Breast Cancer Res. 2007;9(5):R61.

16.

The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor.

To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, Lee C, Yokom DW, Stratford AL, Klinge U, Mertens PR, Chen CS, Bally M, Yapp D, Dunn SE.

Mol Pharmacol. 2007 Sep;72(3):641-52. Epub 2007 Jun 26. Erratum in: Mol Pharmacol. 2014 Mar;85(3):531-2.

17.

PTTG and PBF repress the human sodium iodide symporter.

Boelaert K, Smith VE, Stratford AL, Kogai T, Tannahill LA, Watkinson JC, Eggo MC, Franklyn JA, McCabe CJ.

Oncogene. 2007 Jun 28;26(30):4344-56. Epub 2007 Feb 5.

PMID:
17297475
18.

YB-1 is a Transcription/Translation Factor that Orchestrates the Oncogenome by Hardwiring Signal Transduction to Gene Expression.

Wu J, Stratford AL, Astanehe A, Dunn SE.

Transl Oncogenomics. 2007 May 11;2:49-65. Print 2007.

19.

Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity.

Kim DS, Franklyn JA, Smith VE, Stratford AL, Pemberton HN, Warfield A, Watkinson JC, Ishmail T, Wakelam MJ, McCabe CJ.

Carcinogenesis. 2007 Mar;28(3):749-59. Epub 2006 Oct 27.

PMID:
17071631
20.

Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer.

Kim DS, Franklyn JA, Stratford AL, Boelaert K, Watkinson JC, Eggo MC, McCabe CJ.

J Clin Endocrinol Metab. 2006 Mar;91(3):1119-28. Epub 2006 Jan 4.

PMID:
16394085
21.

Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells.

Kim D, Pemberton H, Stratford AL, Buelaert K, Watkinson JC, Lopes V, Franklyn JA, McCabe CJ.

Oncogene. 2005 Jul 14;24(30):4861-6.

PMID:
15897900
22.

Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis.

Stratford AL, Boelaert K, Tannahill LA, Kim DS, Warfield A, Eggo MC, Gittoes NJ, Young LS, Franklyn JA, McCabe CJ.

J Clin Endocrinol Metab. 2005 Jul;90(7):4341-9. Epub 2005 May 10.

PMID:
15886233
23.

PTTG's C-terminal PXXP motifs modulate critical cellular processes in vitro.

Boelaert K, Yu R, Tannahill LA, Stratford AL, Khanim FL, Eggo MC, Moore JS, Young LS, Gittoes NJ, Franklyn JA, Melmed S, McCabe CJ.

J Mol Endocrinol. 2004 Dec;33(3):663-77.

PMID:
15591026
24.

Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors.

McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ.

J Clin Endocrinol Metab. 2002 Sep;87(9):4238-44.

PMID:
12213878

Supplemental Content

Loading ...
Support Center